Pegylated interferon for chronic hepatitis B

To assess the beneficial and harmful effects of pegylated interferon alpha-2a (40 kilodalton (kd)) or pegylated interferon alpha-2b (12 kd) alone or in combination with other drugs, as compared with no treatment, placebo, or other antiviral drugs (except adefovir dipivoxil) for chronic hepatitis B, with HBeAg-positive or HBeAg-negative status.

This is a protocol.